secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001104659-24-056146
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics amends ATM sales agreement with A.G.P., terminates B. Riley
-----------------------------------------------------------------------------

- Entered Amendment No. 2 to At Market Issuance Sales Agreement with A.G.P./Alliance Global Partners on May 2, 2024.
- Amendment updates registration statement to new Form S-3 filed May 2, 2024 for future at-the-market offerings.
- B. Riley Securities, Inc. agreed to termination as party to the Sales Agreement effective May 1, 2024.
- Other terms of the original agreement remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465924056146/0001104659-24-056146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465924056146/tm2413223d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-056146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer